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Abstract 
Dysfunctions of the gastrointestinal tract are thought to be related to disturbances or 10 
aberrancies of the intestinal microbiota. Nowadays probiotics may represent a solution 
of choice to balance gut microbiota although they have not been selected for specific 
subpopulations or disease groups. Since probiotic health benefits are strain specific, it is 
likely that strains can be selected aimed at particular groups of patients.  
Probiotics have been usually used to treat and prevent some gastrointestinal 15 
disturbances such as irritable bowel diseases (IBD) or syndrome (IBS), or diarrhoea, 
although new extra-intestinal applications are the getting interest of industry and 
consumers. This review shows the current and new applications of probiotics to 
improve human health.  
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Introduction 
Gastrointestinal tract (GIT) microbiota plays an important role in human health due to 
its essential participation in digestion and nutrient assimilation, as well as its immune 
modulating functions. The populations of bacterial species in the gut vary between 
individuals, they are influenced by the environment and, although flexible, microbial 5 
populations in the gut are finely tuned and very sensitive to infectious processes 
(Kurokawa et al., 2007; Palmer et al., 2007). Also, the GIT microbial profile varies in 
immunological or inflammatory disease patients, metabolic syndrome and even in 
children with autism (Sekirov et al., 2010). Furthermore, recent findings suggest that 
specific gut microbial imbalances are associated with enhanced risks of specific 10 
diseases. A sensible option to restore the lost balance in a complex microbial 
community may be the introduction of bacterial species (probiotics) that will restitute it. 
Probiotics are defined as “live microorganisms that, when administered in adequate 
amounts, confer a health benefit to the host” (FAO/WHO, 2002). They are commonly 
isolated from human samples and are externally administrated helping in the recovery 15 
and maintenance of the microbial balance. Probiotics have become popular in a number 
of food products which are commercially available worldwide. They are also found with 
increasing frequency as nutritional supplements, freeze dried in sacchettes or capsules. 
Most of them belong to the genera Lactobacillus or Bifidobacterium, although there are 
remarkable exceptions, such as Saccharomyces boulardii (McFarland et al., 1995), 20 
Escherichia coli Nissle 1917 (Kruis et al., 1997) or some Bacillus species (Duc et al., 
2004; Hong et al., 2008).  
During the last ten years, health and wellbeing have been one of the strongest market 
drivers for the food industry. Therefore, national and supranational regulatory agencies 
have intervened to warrant the proper use of the terms and concepts also demanding 25 
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solid scientific evidence for any health claim used in functional foods such as probiotics 
(http://nccam.nih.gov/health/probiotics/; EU Reglament 1924/2006EU). This has 
reinforced research and remarkable advances have been achieved in our knowledge on 
targets and modes of action. There are hundreds of scientific publications describing 
different effects of the probiotic intake in humans, then, meta-analyses and reviews 5 
evaluated the level of scientific evidence for clinical use attained by those studies (Gill 
and Guarner, 2004; Williams, 2010). Hence, from the clinical perspective, solid 
scientific evidences on their beneficial effects have made probiotics more and more 
frequently prescribed in Modern Medicine.  
The mechanisms of action of probiotics are mostly unknown, however, they must be 10 
necessarily related to their observed effects, and as such, they can be grouped in: anti-
infective (treatment or prevention of viral, yeast or bacteria pathogenesis), metabolic 
functions (amelioration of lactose malabsorption and lowering blood cholesterol) and 
modulation of the immune response system (improvement of immune response, 
amelioration of inflammatory syndromes and immune related pathologies). The anti-15 
infective effects of probiotic bacteria involve mechanisms that imply antagonism with 
other bacteria, or competitive binding to receptors, they can also establish an effective 
communication through biochemical signals with intestinal epithelial cells or mucosa, 
inducing local defense substances (i.e., IgA) in the mucosa (Corr et al., 2009; Ohland 
and MacNaughton, 2010), homeostasis or epithelial integrity (Bäuerl et al., 2011; Di et 20 
al., 2005; van Baarlen et al., 2009; van Baarlen et al., 2010). Those interactions may 
partially explain the mechanisms used by probiotics to improve immune dysfunctions, 
where a wide research field has just been opened. However, the study mechanisms of 
host-probiotic interactions show difficulties that surpass most modern techniques 
utilized. In particular, their interaction with GALT depends upon multiple receptors 25 
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that, altogether elicit different and complex signal transduction pathways. 
Understanding the mechanisms of action of probiotics will help to substantiate Health 
Claims for commercial purposes, but most important, it will explain differences 
between strains and will help to define more precisely all aspect of their health benefits. 
This review is aimed to compile representative scientific evidence showing the great 5 
diversity of applications of probiotics and their future perspectives. 
 
Benefits of probiotics on human health 
This far the lack of a homogeneous regulation has led to the coexistence in the market 
of well studied strains for which health benefits have been demonstrated with others for 10 
which not scientific data are available. The new EU regulation on nutrition and health 
claims made on foods has come into force (Regulation (EC) nº1924/2006) which may 
help to increase research efforts to scientifically substantiate probiotic effects.   
Some of the beneficial effect of probiotic consumption include, among others: 
improvement of intestinal tract health by means of regulation of microbiota and 15 
stimulation and development of the immune system; synthesizing and enhancing the 
bioavailability of nutrients; reducing symptoms of lactose intolerance and reducing risk 
of certain diseases. Several mechanisms of action have been proposed to explain the 
beneficial effects of probiotics. These mechanisms are largely unknown, but may 
involve modifying gut pH, antagonizing pathogens through production of antimicrobial 20 
compounds, competing for pathogen binding, receptor sites, nutrients and growth 
factors, stimulating immunomodulatory cells, and producing lactase [ref]. 
Probiotics have specific targets of action that are probiotic-dependent as different 
bacterial strains may differ with respect to their effects on health. In addition, it must be 
taken into consideration that these mechanisms may be multi-factorial processes and 25 
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also, dependent on each probiotic strain that may have specific functions affecting to the 
health host. Considering their possible targets, probiotics would be designed and applied 
in specific diseases based on their characteristics and health-promoting effects. 
Different levels of host-microbe interaction can be distinguished: i) bacteria-gut 
epithelium interaction: adhesion to mucosal and epithelial cells, stimulation of mucus 5 
secretion and enhancing the production of defensive molecules such as mucins and 
defensins, increasing and reinforcing barrier function, innate immune function, reducing 
the secretory and inflammatory consequences of bacterial infection and improving gut 
motility; ii) bacteria-immune system interaction: Immune-modulation and regulation 
of immune responses beyond the gut and finally, iii) bacteria-bacteria interaction: 10 
Modify microbiota to suppress and inhibit pathogens and prevention of their adhesion, 
establishment and/or replication of pathogens in the gastrointestinal tract, secretion of 
antimicrobial substances and compounds, compete for nutrients necessary for pathogen 
survival and anti-toxin effects. The general mechanisms by which probiotics may have 
an effect can be divided into three main categories: normalization of microbiota, 15 
modulation of immune response, and metabolic functions.  
Traditionally probiotics have been tested for several different potential benefits, in the 
hope that the strain will have some of the tested effects. However, since probiotic health 
benefits are strain specific, it is likely that strains can be selected aimed at particular 
groups of consumers. Also particular patient groups may require specific probiotics 20 
strains aimed at the groups’ particular needs.  In addition to efficacy, an assessment of 
the cost and need for routine use of probiotics should also be conducted in order to 
identify those areas where probiotics are more likely to be used and they may have a 
deeper effect. Therefore, an alternative would be to rationally select strains for a 
specific health benefit. In spite of the lack of scientific rationale on the traditional 25 
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selection procedures, the results of human clinical studies have produced good evidence 
on the health effects of specific probiotic strains. However, many other proposed health 
effects still require rigorous clinical studies to prove their health promoting potential. As 
the use of specially selected new probiotics to maintain health must be considered even 
more promising, the selection criteria need to be revised.  5 
 
Current Intestinal Applications  
Probiotics have been traditionally used in cases of intestinal discomfort. It has been 
known for a long time that fermented dairy products containing live bacteria are better 
tolerated than milk by lactose intolerant subjects. Among the current intestinal 10 
applications of probiotics the beneficial effects of specific strains shortening the 
duration and preventing the episodes of diarrhoea are the best documented. 
Interestingly, their effect on constipation has also been evaluated. The role of probiotics 
on inflammatory bowel disease and irritable bowel syndrome has been the subject of 
several recent studies. During the last years probiotic beneficial effects on Helicobacter 15 
pylori infection, colorectal cancer or necrotizing enterocolitis have also been assessed. 
Some beneficial intestinal effects of certain probiotic strains can be considered well 
established which has lead to the publication of recommendations for their use in 
clinical practice (Floch et al. 2008).  
 20 
Lactose intolerance  
A significant part of the population shows reduced levels of -galactosidase in the small 
intestine, suffering intolerance symptoms when lactose is ingested. Several studies have 
shown that lactose-intolerant subjects suffer fewer symptoms if milk is replaced by 
fermented dairy products. The bacterial enzyme -galactosidase, which can be detected 25 
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in the small intestine after consumption of viable yoghourt, appears to be the major 
factor improving digestibility by hydrolysing the lactose. It is important to underline 
that different strains may have very different -galactosidase activities and thus differ in 
their efficacy. Another factor suggested to have a role is the slower gastric emptying of 
semi-solid milk products compared with milk. Modulation of the intestinal microbiota 5 
composition and activity may also play a role alleviating lactose intolerance (He et al. 
2008). 
 
Diarrhoea 
Diarrhoea is an obvious target for probiotics and their role on infant diarrhoea is the best 10 
studied probiotic effect. Several human intervention studies indicate a clear positive 
effect of specific probiotic strains on both, rotavirus and antibiotic-associated diarrhoea. 
In fact, probiotics are considered among the alternatives for management of acute 
gastroenteritis in children (Guarino et al. 2008). Results for traveller´s diarrhoea, 
although encouraging, are less convincing. As with any other probitotic effect the 15 
beneficial effects reported in the studies are specific to the strains used. 
 
Roravirus diarrhoea. Shortening the duration of rotavirus diarrhoea using specific 
probiotic strains is well documented. Several studies around the world reported 
beneficial effects (Kotowska et al. 2005, Weizman et al. 2005, Szymanski et al. 2006). 20 
Some meta-analyses have evaluated the effects of probiotics in general concluding that 
probiotics reduce the duration or frequency of diarrhoea in children (Huang et al. 2002, 
Van Niel et al. 2002, Allen et al. 2004). The main criticism to these meta-analyses is 
that often they considered probiotics as a group. Different probiotics have varying 
effects on the duration of diarrhoea and the immune response in children with acute 25 
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gastroenteritis. Thus, it is important to remember that the reported studies are specific to 
the strains used. The increasing number of studies conducted during the last years 
allowed to carry out meta-analyses focused on specific strains. These studies showed 
that, at least, the strains Lactobacillus rhamnosus GG and S. boulardii are effective in 
treatment of acute diarrhoea in children (Sazawal et al. 2006, Szajewska et al. 2007a, b). 5 
 
Antibiotic-associated diarrhoea. The efficacy of probiotics reducing this common kind 
of diarrhoea has been extensively studied and the results are convincing for a number of 
probiotics. Meta-analyses conducted in this area (Sazawal et al. 2006, Johnston et al. 
2007) concluded that the available data provides sufficient evidence for the role of 10 
probiotics in the prevention of antibiotic-associated diarrhoea. For some specific 
probiotics such as L. rhamnosus GG and S. boulardi strain-focused meta-analysis have 
also indicated a beneficial effect of the strains (McFarland 2006, Szajewska et al. 2006). 
 
Traveller’s diarrhoea. There are a few studies reporting a positive effect of probiotics 15 
for reducing the risk of traveller’s diarrhoea . However, inconsistent results have often 
been reported with unexplained geographic differences in protection rates (Koo and 
Dupont 2006). The different aetiology of the disease depending on the destination and 
differences in the probiotic strains, dosages and administration vehicles used makes the 
comparison of studies difficult. A recent meta-analysis reports a beneficial effect of 20 
certain strains in the prevention of traveller’s diarrhoea (McFarland 2007). However, 
information on large-scale studies using defined strains is still lacking. 
 
 
 25 
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Inflammatory Bowel Disease 
Crohn’s disease, ulcerative colitis (UC) and pouchitis constitute a group of diseases 
whose aetiologies are not well understood and that are characterised by deregulation of 
the immune system leading to gut inflammation. This group of diseases is commonly 
regarded as inflammatory bowel disease (IBD). A disturbance of gut microbiota or an 5 
inadequate host response to it has been shown to play a role in the pathogenesis of IBD 
(Manichanh et al. 2006; Qin et al. 2010). The effect of different probiotics on IBD has 
been evaluated with variable results.  
The greatest evidence for efficacy of probiotics on IBD has been shown for the 
prevention of pouchitis. Different human intervention trials have shown effectiveness of 10 
the probiotic preparation VSL3 in maintaining remission of pouchitis (Gionchetti et al. 
2003, Mimura et al. 2004). A non-pathogenic E. coli strain (Nissle 1917) was shown to 
be as effective as the standard treatment (masalazine) in maintaining remission of UC 
(Kruis et al. 2004) and the mix VSL3 was suggested to induce remission and to improve 
status in UC patients (Bibiloni et al. 2005), supporting the use of probiotics. L. 15 
rhamnosus GG was found to prolonge the relapse-free time, although no effect on 
relapse rate was observed (Zocco et al. 2006) and some positive results have also been 
reported for S. boulardi (Guslandi et al. 2003). In contrast, trials evaluating the 
application of different probiotics on Crohn’s disease have not been too successful 
(Prantera et al. 2002, Marteau et al. 2006) and only some preliminary studies reported 20 
modest beneficial effects (Guslandi et al. 2000, Guandalini et al. 2002).  
Some reviews and meta-analysis studies (Elahi et al. 2007, Mallon et al. 2007) focused 
on the use of probiotics on IBD concluded that further research is still needed. 
 
Irritable Bowel Syndrome 25 
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Irritable Bowel Syndrome (IBS) affects a significant part of the western population 
being the first cause of visit to the gastroenterologist. IBS is characterised by intestinal 
discomfort or pain and altered bowel function with diarrhoea and constipation. 
Although the aetiology if the disease is not well understood, in IBD patients an altered 
brain response to visceral stimuli appears to occur (Naliboff et al. 2001) causing pain or 5 
discomfort due to visceral hypersensitivity. An altered gut microbiota has also been 
reported in IBS patients (Nobaek et al. 2000, Pimentel at al. 2000) providing the basis 
for probiotic theraphy. In a study using Lactobacillus plantarum 299v a reduction of 
symptoms was observed (Niedzelin et al. 2001) and reductions of bloating and 
flatulence have also been reported for the probiotic mix VSL3 (Kim et al. 2003, 2005). 10 
However, the limited number of individuals included in these studies requires further 
confirmation in larger trials. Contrary to this no reduction of symptoms was observed 
with other strains (Drouault-Holowacz et al. 2008). Recently it has been shown that oral 
administration of specific Lactobacillus strains induces the expression of opioid and 
cannabinoid receptors in intestinal epithelial cells (Rousseaux et al. 2007). Such 15 
reaction mediates gut analgesic effects indicating that the gut microbiota composition 
and its modulation through probiotics can influence our visceral perception which 
constitutes a new approach to modulate the manifested visceral hypersensitivity of IBD 
patients.  
During the last years large studies have been conducted reporting beneficial effects with 20 
some strains and probiotic mixes (Kajander et al. 2008, Whorwell et al. 2006, Guyonnet 
et al. 2007). A recent meta-analysis concludes that although some specific strains or 
mixes may have a beneficial effect further large well designed studies are needed 
(Mcfarland and Dublin 2008).  
 25 
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Helicobacter pylori therapy 
H. pylori is a worldwide spread infectious agent that colonizes the stomach causing 
gastritis, peptic ulcer and gastric cancer. Animal and human studies have reported the 
inhibitory effect of certain lactobacilli preventing infection and colonization (Coconnier 
et al. 1998, Wang et al. 2004) or reducing bacterial load (Francavilla et al. 2008). A 5 
good in vitro inhibition was observed for Lactobacillus johnsonii La1 and the strain has 
positive effects when consumed during eradication therapy (Felley et al. 2001). In a 
multicentre study the consumption of a fermented milk containing Lactobacillus casei 
DN-114001 increases the eradication efficacy of the standard treatment in children 
(Sykora et al. 2005). Similar results have been reported in adults with a probiotic 10 
yoghourt (Kim et al. 2008). Furthermore, probiotics may have other beneficial effects in 
the setting of H. pylori antibiotic therapy by alleviating the side-effects associated with 
the standard antibiotic treatment (Myllyluoma et al. 2005, Cindoruk et al. 2007).  
Gotteland and coworkers (2006) reviewed this topic concluding that probiotics may not 
be effective eradicating H. pylori but in combination with the standard treatment they 15 
may increase eradication rates and/or reduce side-effects.  
 
Constipation 
Constipation is a common intestinal disorder due to deregulation of the motor activity in 
the large intestine that affects a significant part of the western population. Probiotics 20 
have been suggested to relieve constipation and LAB-containing fermented products 
have been used to this end. The strains B. lactis DN-173 010, L. casei Shirota or L. 
johnsonii La1 have been reported to be beneficial (Marteau et al. 2002, Koebnick et al. 
2003, Fukushima et al. 2004). 
 25 
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Necrotizing enterocolitis (NEC) 
Recent studies suggest that certain probiotics can reduce both the severity and incidence 
of NEC in preterm neonates (Hoyos 1999, Bin-Nun et al. 2005, Lin et al. 2005) whilst 
no effect has been observed with other probiotic strains (Dani et al. 2002), underlining 
the high strain-specificity of probiotics. A meta-analysis study concluded that probiotics 5 
may be effective in reducing the risk of NEC in low-birth weight infants but more 
research is needed to clarify their safety, appropriate dose and type of probiotic to be 
used (Deshpande et al. 2007). 
 
Colorectal cancer 10 
Colorectal cancer is the third most common cancer and it seems to be strongly linked to 
dietary habits (Bingham et al. 2003). The association between gut microbiota 
composition and risk of colon cancer has been a subject of discussion for many years 
(Moore and Moore 1995, Hope et al. 2005). Some reports appear to indicate that not 
just the faecal microbiota but the colonic mucosa microbiota may be altered in these 15 
patients (Gueimonde et al. 2007). A potential role for probiotics in the prevention of this 
form of cancer has often been suggested. However most of the available evidence is 
indirect being based on in vitro and animal studies. There are also some case-control 
studies supporting an inverse relationship between consumption of yoghourt and risk of 
colon cancer (Rowland 2004). However, long-term trials as well as epidemiological 20 
studies are needed before any conclusion may be established. 
 
 
 
Current Extra-Intestinal Applications  25 
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Urinary tract and vaginal infections  
A healthy vaginal microbiota is characteristically dominated by lactobacilli, which are 
known to provide colonization resistance and prevent the infections by means of 
different mechanisms including: specific adhesion sites at the epithelial surface of the 
urinary tract; pH control and the production of antimicrobial substances like acids, 5 
hydrogen peroxide and bacteriocines; degradation of polyamines; and also, production 
of surfactants, which have anti-adhesive properties against the adhesion of pathogens (; 
Boskey et al., 1999; Aroucheva et al., 2001; Reid, 2001). The balance can be disturbed  
to a complex multispecies microbiota including the overgrowth of indigenous bacteria 
of the vagina like Gardnerella, Bacteroides, Peptostreptococcus, Prevotella spp. or 10 
aerobic cocci, or by the invasion of foreign microorganisms, such as E. coli, 
Enterococcus faecalis, Enterobacteriaceae, staphylococci or Candida, may lead to 
urinary tract infections and bacterial vaginosis (Xie et al., 2006; Fredriks et al., 2005; 
Reid et al., 2008; Kirvajainen et al., 2009).  
Some Lactobacillus including strains of L. gasseri, L. acidophilus and L. salivarius have 15 
been found to have an inhibitory effect on the in-vitro growth of pathogens such as G. 
vaginalis, Bacteroides spp., or Prevotella bivia that may cause infections (Mastromarino 
et al. 2002; McLean and Rosenstein 2000). Production of lactic acid by lactobacilli, 
which is mainly responsible for the low vaginal pH, contributes to the inhibition of 
growth of G. vaginalis. In addition, production of bacteriocins by some Lactobacillus 20 
strains has also been found to play a role in the inhibition of growth of G. vaginalis 
(Aroutcheva et al., 1991; Simoes et al., 2001). Some in-vitro studies have also shown 
that specific strains of lactobacilli are able to aggregate with G. vaginalis and inhibit the 
adherence and/or to displace previously adhered pathogens from vaginal epithelial cells 
(Boris et al., 1998; Mastromarino et al., 2002). Most relevant clinical trials have 25 
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suggested that oral administration of lactobacilli, is able to increase the numbers of 
vaginal Lactobacillus, restore the vaginal microbiota to normal, and treat women 
suffering bacterial vaginosis, although some trials found that intra-vaginal 
administration had no significant effect (Falagas et al., 2007). Although the high 
number of available studies and results concerning the effectiveness of the 5 
administration of lactobacilli for the treatment of bacterial vaginosis are mostly positive, 
its needed further studies to conclude definitively that probiotics are useful (Falagas e 
al., 2007).  
 
Allergic diseases (Atopic disease, eczema and rhinitis and asthma) 10 
The prevalence of allergic diseases continues to increase in the developed world and 
constitutes a common health problem among children (Asher et al. 2006; von Mutius 
1998). Atopic disease develops in the first years of life, and other allergic processes can 
gradually manifest over time. The condition usually manifests initially in the form of 
food allergy and atopic dermatitis, followed in later stages by other problems as 15 
respiratory allergy with rhinitis and/or asthma. This has led to the adoption of 
preventive measures in those nursing infants at highest risk of developing atopy. 
However, these are very complex diseases involving the intervention of a broad range of 
etiopathogenic factors: environmental, genetic and epigenetic. Microbiota aberrancies 
have been related to the development of allergic diseases (Kalliomaki et al., 2001; 20 
Kalliomaki and Isolauri, 2003). A reduced ratio of bifidobacteria to clostridia has 
appeared in infants developing atopy (Kalliomäki et al. 2001), and allergic patients have 
been shown to be more often colonized with Clostridium and Staphylococcus, and have 
fewer Enterococcus and Bifidobacterium than do non-allergic patients (Björksten et al. 
2001; Kalliomäki et al. 2001; Watanabe et al. 2003). Gut microbiota composition may 25 
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precede the development and manifestation of atopic outcomes, while early colonisation 
with Escherichia coli has been associated with higher risk for developing eczema, and 
Clostridium difficile with eczema, recurrent wheeze, and allergic sensitization in 
infancy (Penders et al. 2007). The Hygiene Hypothesis supports the rapid increase of 
atopy related to lower microbe exposure at early life and subsequent lower number of 5 
infections during infancy (Strachan, 1989).These changes on microbiota may be 
counter-balanced by probiotic bacteria, and also, positive clinical effects on the 
prevention and treatment of atopic diseases of probiotics have been reported (Majamaa 
and Isolauri 1997; Isolauri et al. 2000; Kalliomäki et al. 2001b, 2003; Rosenfeldt et al. 
2003; Viljanen et al. 2005b; Abrahamsson et al. 2007).The effectiveness of L. 10 
rhamnosus GG in the prevention of atopic dermatitis has been reported in randomized, 
controlled trials (Kalliomaki et al., 2001; 2003). L. rhamnosus GG was given to 
pregnant women for four weeks prior to delivery, then to newborns at high risk of 
allergy for six months with the result that there was a significant reduction in early 
atopic disease (Kalliomaki, 2003). In other clinical studies with infants allergic to cow’s 15 
milk and also, atopic dermatitis was alleviated by ingestion of probiotic strains L. 
rhamnosus GG and B. lactis Bb12 (Majamaa and Isolauri, 1996; 1997; Isolauri et al., 
2000). Furthermore, several well-designed studies have provided evidence that specific 
strains of probiotics can be somewhat effective in treatment of established atopic 
dermatitis (Rosenfeldt et al. 2003; Viljanen et al. 2005; Weston et al. 2005). In other 20 
studies, L. rhamnosus GG was combinated with other probiotic strains, L. rhamnosus 
LC705, B. breve Bb99, and Propionibacterium freudenreichii subsp. shermanii JS in 
order to determine the impact on the cumulative incidence of allergic diseases 
(Kukkonen et al. 2007). This study showed no effect on incidence of all allergic 
diseases, but the treatment did significantly prevent atopic eczema.  Two studies 25 
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showed a preventive effect of probiotic supplementation on the development of eczema 
at the age of 2 years, with a relative risk reduction of 50% (Kalliomaki et al., 2001 ) and 
26% (Kukkonen et al., 2007). In a third study, the cumulative incidence of eczema was 
similar in intervention and placebo group, but less atopic eczema was observed in the 
intervention group (Abrahamsson et al., 2007). In two studies, supplementation of 5 
probiotic bacteria failed to reduce the risk of atopic dermatitis and resulted in increased 
sensitization to allergens in one study (Taylor et al., 2007; Kopp et al., 2008). A major 
reason for these discrepant clinical results may be the use of different probiotic strains 
or preparations. In this respect, however, it is interesting that the results of Kopp et al. 
(2008) are in sharp contrast with the study of Kalliomaki et al., (2001 lancet) although 10 
an identical probiotic strain is used (LGG) in an also otherwise comparable study 
design. Other study (Niers et al., 2009) indicates that the beneficial effects of probiotic 
bacteria are established within the first 3 months of life. It reported a relative risk 
reduction of 58% of parental reported eczema at 3 months of age being the effect 
sustained until the age of 2 years, although relative risk reduction decreased with age. 15 
On the contrary, a recent meta-analysis (Boyle et al., 2009) including 12 randomized-
controlled trials (781 participants) conclude that probiotics are not a clinically effective 
treatment for eczema, although when given during early infancy for the prevention 
rather than the treatment of eczema the results for some probiotic strains are promising. 
The effects that probiotics have on intestinal permeability, intestinal inflammation, 20 
microbiota composition and host immune responses may be insufficient to lead to the 
resolution of established eczema, but sufficient when used in early life for the 
prevention of such disease. One potential criticism of this meta-analysis is the low 
number of studies and the inclusion of heterogeneous studies using different probiotic 
strains. 25 
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A recent study (Vliagoftis et al., 2008) evaluated the clinical evidence for the use of 
probiotics as a therapeutic modality for allergic rhinitis and asthma. Probiotics may 
have a beneficial effect in allergic rhinitis by reducing symptom severity and medication 
use, although, further good-quality studies are needed (Hatakka et al., 2000). Indeed, 
Lactobacillus paracasei might improve the quality of life of adolescents with perennial 5 
allergic rhinitis (Peng et al 2005; Wang et al., 2004). To examine whether long-term 
consumption of fermented milk containing a specific Lactobacillus casei may improve 
the health status of children suffering from allergic asthma and/or rhinitis a randomized, 
prospective, double blind, controlled trial was conducted (Giovanini et al, 2007). In 
children with rhinitis, the annual number of rhinitis episodes was lower in the 10 
intervention group, and also the mean duration of an episode of diarrhea was lower in 
the intervention group. While long-term consumption of fermented milk containing 
Lactobacillus casei may improve the health status of children with allergic rhinitis no 
effect was found in asthmatic children (Giovanini et al, 2007).  
 15 
Oral cavity  
The microflora of the oral cavity is comprised of more than 500 bacterial species 
(Dewhirst et al. 2009). The most prominent cariogenic bacterium is Streptococcus 
mutans, but many lactobacilli have cariogenic properties too. The composition of the 
oral microflora is influenced by bacterial transfer at birth, the gastrointestinal flora, the 20 
composition of the saliva and by other factors. The long-term composition is 
remarkably stable and does not vary with individual meals. The main focus in the 
studies of potential oral probiotics has been on caries prevention, especially on the 
possibility of reducing the number of mutans streptococci when products containing 
certain probiotic strains are used (Haukioja et al., 2008). The caries bacteria colonize 25 
 18 
acidic environments, such as fissures and interdental spaces, and produce acids from 
fermentable sugars. On the contrary there was a suggestion that temporary colonization 
of a nonlactose and slow sugar fermenting bacteria, which are able to inhibit the caries 
pathogens, may prevent caries in children (Meurman et al., 1994, Nasse et al., 2001). 
Other possible applications, like the reduction of the number of oral Candida or of 5 
microflora associated with oral malodour, have also been investigated. 
The probiotic strains most studied in relation to the colonization of mutans streptococci 
are L. rhamnosus GG and L. reuteri ATCC 55730 (Ahola et al., 2002; Caglar et al., 
2005, 2006 ; Meurman et al., 1995; Näse et al., 2001; Nikawa et al., 2001). In some 
studies the use of products containing these bacteria has been found to reduce oral 10 
mutans streptococci (Näse et al., 2001; Nikawa et al., 2001; Caglar et al., 2006). L. 
rhamnosus GG can be found in the oral cavities of volunteers who are using products 
containing this bacterium (Yli-Knuuttila et al., 2006). Colonization by L. reuteri 
SD2112 has not been studied, but the products containing it do not increase the 
lactobacillus counts in saliva (Canglar et al., 2006). Other probiotic strains have also 15 
been studied but with contradictory results: for example, a product containing 
Bifidobacterium DN-173010 seems to decrease the number of mutans streptococci in 
saliva (Canglar et al., 2005), but Montalto et al. (2004) did not find any effect of 
probiotic treatment on salivary counts. 
Although several studies have shown that some probiotic bacteria may affect oral 20 
ecology, the mechanisms are largely unknown. A recent study (Haukioja et al., 2008) 
showed that probiotic bacteria that bound to saliva-coated hydroxyapatite reduced the 
adhesion of S. mutans but the inhibitory effect on the adherence of S. gordonii was 
lower. Salivary pellicle protein composition was modified by all the strains tested. 
Further studies are needed on this filed to clarify the potential role of probiotics. 25 
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Skin diseases 
The normal human skin microflora is variable according to location and composed of a 
limited number of microbial types (Grice et al. 2009). The resident microbiota fills a 
niche that could otherwise be colonized by pathogenic microorganisms that are 5 
aggressive and cause infection, either at the skin site or by transfer to other sites. Also, 
if the skin could be colonized by pathogens adopted for other sites (e.g. mucous 
membranes), and this could facilitate the spread of pathogens by offering them more 
dispersed routes. 
As stated above, a significant improvement on the course of atopic dermatitis (Isolauri 10 
et al., 2000) and also, probiotics may be able to reduce the prevalence of atopic eczema 
in children at high risk for atopic diseases (Kalliomaki et al., 2001) have been described. 
The suggested mechanistic base of skin effects induced by probiotic strains is 
represented by changes in systemic immune responses. In particular, modulation of 
specific T-cell subsets such as stimulation of TH1 cells in the gut mucosa which may 15 
subsequently influence immune responses in other tissues may play a role (Pohjavuori 
et al., 2004; Lammers et al., 2003, Prescott et al., 2005). In mice, oral administration of 
Lactobacillus casei reduced contact hypersensitivity to a hapten only in the presence of 
CD4+ T-cells, which control the size of the CD8+ effector pool (Chapat et al., 2004). 
Nutritional supplementation of mice with Lactobacillus johnsonii provided protection of 20 
the skin immune system against ultraviolet B radiation-induced immunosuppressive 
effects (Gueniche et al., 2006). Similar effects have recently been described in a human 
in vivo study and it has been proposed that oral consumption of probiotic bacteria may 
represent a novel approach to protect the skin immune system against ultraviolet 
radiation (Bouilly et al.,2008). Another target for probiotics may be skin barrier 25 
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function. A recent double-blind, randomized clinical study has shown that a 24-week 
skin nutrition  intervention with a fermented dairy product in female volunteers having 
dry and sensitive, but otherwise healthy skin significantly reduced transepidermal water 
loss and thus improved stratum corneum barrier function compared to a placebo product 
(Punch et al., 2008). It should be noted, however, that in addition to the probiotic strains 5 
(L. casei, Lactobacillus bulgaris and Streptococcus thermophilus) this dairy product 
contained a mixture of boretsch oil, green tea polyphenols and vitamin E and that skin 
barrier improvement may be at least in part due to these ingredients. In general, 
nonintestinal applications of probiotics are few and have thus far mainly been used for 
the urogenital tract. There are currently only a very few studies pursuing a probiotic 10 
approach for the skin bacterial composition. Ouwehand et al. (2003) point out the 
difficulty to identify useful bacteria in view of the environmental conditions that may 
prevent colonization of skin with a probiotic strain.  
 
Obesity and Insulin Control  15 
The prevalence of obesity is rapidly increasing in Western society, constituting an 
important health issue. Obesity is the result of a positive imbalance between energy 
intake and energy expenditure over a long period of time and its related to the 
development of other diseases including diabetes and cardiovascular diseases among 
others. Several genetic and environmental factors influence obesity (Hill et al., 1998; 20 
Jouret et al., 2007) which include diet, socioeconomic status, maternal obesity, rapid 
infancy weight gain, and decreased physical activity. In addition to all of these risks, 
some reports have suggested that the gut microbiota is an important factor affecting 
energy disposal and storage in adipocytes (Ley et al., 2005, Turnbaugh et al., 2006).  
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Experimental research suggests that the nature and composition of the intestinal 
microbiota are altered in obesity (Ley et al., 2005; Turnbaugh et al., 2006). Lean 
individuals have more bacteroides type bacteria, while obese individuals have more 
Firmicutes such as clostridia in their intestinal microbiota (Ley et al., 2005; Turnbaugh 
et al., 2006). It has been proposed that such bacterial composition lead to improved 5 
extraction of energy from the diet and enhanced energy storage in the adipose tissue 
(Turnbaugh et al., 2006).  
In addition, a recent report showed that infants with high numbers of the 
Bifidobacterium and low numbers of Staphylococcus may be protected from excess 
weight gain during later life (Kalliomaki et al., 2008). Since Bifidobacterium genus and 10 
species are prevalent in breast-fed infants, it has been suggested the protective role 
attributed to breast-milk against developing obesity later in life (Wabitsh 2000). In 
addition, it has been reported how diets based on a high intake of protein and/or low 
intake of carbohydrate or low fat consumption may alter microbial composition and 
activity in the large intestine and thus impact on gut health (Cani et al., 2008, Duncan et 15 
al., 2007). Obese humans under dietary intervention, based on low carbohydrate intake 
and high protein intake, showed reductions in  Bifidobacterium, and Roseburia spp. and 
clostridial cluster XIVa levels when carbohydrate intake was decreased, while no 
differences were detected in Bacteroides or other clostridial clusters (Duncan et al., 
2007). Alterations in gut microbiota composition associated with obesity have also been 20 
shown to be reversible by oral transfer of the gut microbiota from lean mice to a germ-
free recipient (Turnbaugh et al., 2006 and 2008) or by administration of prebiotic 
substrates to animal models at least over short-term periods (Cani et al., 2007). 
Therefore, it seems likely that a combination of environmental (e.g. diet) and genetic 
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factors contributes to defining unique combinations of bacteria within an individual, 
which could favor either an obese or lean phenotype. 
Gut microbiota modulation via dietary strategies such as probiotics may offer new 
directions for preventive and therapeutic applications in reducing the risk of overweight 
and obesity and also, metabolic-associated disorders. Lee et al (2006) investigated the 5 
anti-obesity effect of a L. rhamnosus strain that produces conjugated linoleic acid, in 
diet-induced obese mice. After 8 weeks of oral feeding, mice lost weight without 
reducing energy intake. In another study, Martin et al (2008) administered probiotic 
beverages to germ-free mice that had been conventionalized with human infant 
microbiota showed that probiotic exposure resulted in distinct changes in the 10 
microbiome with associated metabolic alterations affecting energy, lipid, and aminoacid 
metabolism. The importance of these findings to energy homeostasis and overall health 
in humans remains to be determined; however, they suggest that probiotics can alter the 
dynamics of the entire gut microbiota and show that these molecular approaches can be 
used to study the metabolic effects of probiotics on the host and the host's microbiome. 15 
 
Cognitive Function and Mental Health  
As indicated above the use of probiotics has been tested for the prevention and 
treatment of different intestinal and extra-intestinal diseases. However the application of 
this approach to other health-related situations has not been assessed to date.  20 
The potential role of probiotics on the gut-brain axis provides another interesting area 
for future research. Consumption of certain probiotic strains may affect cytokine patters 
and it has been shown that these molecules may affect cognitive functions (Wilson et al. 
2002) and gut hormones and neuropeptides may affect the learning process (Diano et al. 
2006). Mental problems, including schizophrenia, anxiety, stress or depression, are 25 
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frequently associated with other disorders in which microbiota disturbances may play a 
role, such as ulcerative colitis, celiac disease, metabolic syndrome or IBS (Peet 2006). 
Also immune parameters have been found to be affected in these patients (Atanackovic 
et al. 2004, Barak 2006). It has been known for a long time that stress (Holdeman et al. 
1976), can affect microbiota composition. Interestingly, a role of the microbiota in the 5 
development of the physiological system of stress response has been suggested (Sudo et 
al. 2004). In a recent animal study a Bifidobacterium infantis strain was found to inhibit 
pro-inflammatory responses, increase plasma levels of tryptophan, which is an 
important serotonergic precursor, and to reduce levels of some monoamine metabolites 
in the brain, suggesting a potential antidepressant effect of the strain (Desbonet et al. 10 
2008). Interestingly, in a trial with a fermented milk containing L. casei Shirota Benton 
and coworkers (2007) observed a potential improvement of mood in healthy subjects. 
These facts open the possibility for the participation of gut microbiota in many 
apparently unrelated physiological processes and diseases. If this is the case 
intervention with probiotics may have an impact on these patients. 15 
 
Inflammation of the joins 
Common genetic and immunologic mechanisms underlay the coincidence of 
inflammation in the bowel and the joints. A recent study reports the association between 
bacterial gastroenteritis and the risk of developing arthritic symptoms (Garg et al. 2008) 20 
and aberrancies on the intestinal microbiota composition have been identified in arthritis 
(Benno et al. 1994, Malin et al. 1996) and spondylitis (Stebbings et al. 2002). 
Rheumatoid arthritis patients harbour bacteria capable of triggering arthritis (Toivainen 
2003) and in fact, bacterial DNA has been found in synovial fluids of these patients 
 24 
(Moen et al. 2005). Thus, gut microbiota together with appropriate immune modulation 
constitute clear targets for probiotics in patients suffering arthropathies.  
 
Conclusion and future perspectives  
Recent advances have been made in the understanding of when to use probiotics and 5 
how they impact specific pathological states. Several evidences support the concept that 
probiotic may have benefits in a multitude of disorders and they exert health promoting 
effects. Clinical efficacy of specific probiotic strains has been demonstrated in some 
diseases as rotavirus’s diarrhea, antibiotic associated diarrhea, irritable bowel syndrome 
and food allergies. In addition, new evidences support the use of probiotics in the 10 
prevention and treatment of a number of diseases including atopic diseases, immune 
disorders, obesity, and diabetes. Further, recent clinical and nutritional studies have 
uncovered the function of specific strains in energy metabolism and thereby have 
opened up new angles on their use and exploitation. However, as these processes are 
highly specific, it is important to characterize the properties the probiotic strains an in 15 
order to select the best strains or strain combinations for the target in question. 
Advances have prompted increase the interest of researchers and industry and new 
applications and targets are being discovered. 
The rapid development of massive sequencing techniques is allowing the flourisment of 
metagenomic studies. The increased knowledge on genomics, microbiota, and 20 
interactions nutrients-genes (nutrigenomics) promises to expand our understanding on 
the interactions between food and health allowing the development of probiotic dietary 
intervention strategies tailored for specific individuals or functions. This is increasing 
enormously our knowledge on the complex gut microbiota composition and activities 
and allowing to identify disturbances on microbiota related to human disease. In general 25 
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any disorder in which an aberrant microbiota or an un-appropriate immune response 
may play a role are potential targets for probiotic intervention, even though they may 
not take place at gut level.  Disturbances on the microbiota have been identified in other 
intestinal disorders, including diverticulitis (Colecchia et al. 2003), and extraintestinal 
conditions, such as elderly people suffering severe frailty (van Tongeren et al. 2005). 5 
Patients with severe systemic inflammatory response syndrome showed lower levels of 
bifidobacteria and lactobacilli and higher levels of pathogenic microorganisms than 
healthy subjects (Shimizu et al. 2006). Reduced levels of bifidobacteria have also been 
shown in multiple sclerosis patients (Wagenfeld 1991). Although, so far probiotics have 
not been tested in these settings, these studies indicate potential targets for the future 10 
development of probiotic products.  
Some intestinal bacteria have been suggested for very specific targets. For instance 
Oxalobacter formigenes may have a potential role to play in the risk reduction for 
kidney stone formation. (Stewart et al. 2004). A Bacteroides strain, able to reduce 
cholesterol, isolated from the gut microbiota of a subject with a high ability to reduce 15 
cholesterol to coprostanol has also been reported (Gerard et al. 2007). Such 
microorganisms may constitute the basis for future targeted probiotic developments. To 
this regard, other areas of the body different to the gastrointestinal and urogenital tracts, 
such as nasopharynx or skin may also provide areas for novel probiotic applications.  
In any case the high strain-specificity of probiotics must always be taken into 20 
consideration. In fact, the strain-specific characteristics can be exploited to select more 
efficacious strains or for selecting probiotics for specific targets or populations. 
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